APM
Price
$0.74
Change
+$0.01 (+1.37%)
Updated
Apr 9 closing price
Capitalization
5.29M
MDXG
Price
$7.16
Change
+$0.30 (+4.37%)
Updated
Apr 9 closing price
Capitalization
1.06B
26 days until earnings call
Ad is loading...

APM vs MDXG

Header iconAPM vs MDXG Comparison
Open Charts APM vs MDXGBanner chart's image
Aptorum Group
Price$0.74
Change+$0.01 (+1.37%)
Volume$26.41K
Capitalization5.29M
MiMedx Group
Price$7.16
Change+$0.30 (+4.37%)
Volume$864.45K
Capitalization1.06B
APM vs MDXG Comparison Chart
Loading...
APM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APM vs. MDXG commentary
Apr 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APM is a Hold and MDXG is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 10, 2025
Stock price -- (APM: $0.74 vs. MDXG: $7.16)
Brand notoriety: APM and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APM: 35% vs. MDXG: 153%
Market capitalization -- APM: $5.29M vs. MDXG: $1.06B
APM [@Biotechnology] is valued at $5.29M. MDXG’s [@Biotechnology] market capitalization is $1.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APM’s FA Score shows that 1 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • APM’s FA Score: 1 green, 4 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than APM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APM’s TA Score shows that 4 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • APM’s TA Score: 4 bullish, 4 bearish.
  • MDXG’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both APM and MDXG are a good buy in the short-term.

Price Growth

APM (@Biotechnology) experienced а -15.80% price change this week, while MDXG (@Biotechnology) price change was -6.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.46%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -19.62%.

Reported Earning Dates

APM is expected to report earnings on Apr 28, 2023.

MDXG is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (-7.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDXG($1.06B) has a higher market cap than APM($5.29M). MDXG has higher P/E ratio than APM: MDXG (24.50) vs APM (2.39). MDXG YTD gains are higher at: -25.572 vs. APM (-73.571). MDXG has higher annual earnings (EBITDA): 64.3M vs. APM (-9.6M). MDXG has more cash in the bank: 104M vs. APM (2.01M). APM has less debt than MDXG: APM (3.28M) vs MDXG (18.8M). MDXG has higher revenues than APM: MDXG (349M) vs APM (431K).
APMMDXGAPM / MDXG
Capitalization5.29M1.06B1%
EBITDA-9.6M64.3M-15%
Gain YTD-73.571-25.572288%
P/E Ratio2.3924.5010%
Revenue431K349M0%
Total Cash2.01M104M2%
Total Debt3.28M18.8M17%
FUNDAMENTALS RATINGS
APM vs MDXG: Fundamental Ratings
APM
MDXG
OUTLOOK RATING
1..100
275
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
9138
PRICE GROWTH RATING
1..100
9457
P/E GROWTH RATING
1..100
4212
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APM's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for MDXG (73) in the Biotechnology industry. This means that APM’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as APM (100) in the Pharmaceuticals Major industry. This means that MDXG’s stock grew similarly to APM’s over the last 12 months.

MDXG's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for APM (91) in the Pharmaceuticals Major industry. This means that MDXG’s stock grew somewhat faster than APM’s over the last 12 months.

MDXG's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for APM (94) in the Pharmaceuticals Major industry. This means that MDXG’s stock grew somewhat faster than APM’s over the last 12 months.

MDXG's P/E Growth Rating (12) in the Biotechnology industry is in the same range as APM (42) in the Pharmaceuticals Major industry. This means that MDXG’s stock grew similarly to APM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APMMDXG
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 25 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 7 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Ad is loading...
APM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LHCIX16.71N/A
N/A
Lord Abbett Health Care I
ASDEX102.06N/A
N/A
American Century Select R6
MFVFX12.37N/A
N/A
MassMutual Equity Opports R4
PXLIX10.67N/A
N/A
Impax Large Cap Fund Institutional
VYMSX15.89N/A
N/A
Voya Mid Cap Research Enhanced Index I

APM and

Correlation & Price change

A.I.dvisor indicates that over the last year, APM has been loosely correlated with PHGE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if APM jumps, then PHGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APM
1D Price
Change %
APM100%
+0.95%
PHGE - APM
60%
Loosely correlated
-0.12%
PGEN - APM
32%
Poorly correlated
+18.80%
EYEN - APM
32%
Poorly correlated
+3.82%
MDXG - APM
29%
Poorly correlated
+4.37%
BMNDF - APM
27%
Poorly correlated
N/A
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+4.37%
AXON - MDXG
47%
Loosely correlated
+10.98%
VCYT - MDXG
42%
Loosely correlated
+12.88%
OMER - MDXG
39%
Loosely correlated
+7.46%
ARRY - MDXG
39%
Loosely correlated
+13.82%
RAPT - MDXG
38%
Loosely correlated
-2.59%
More